(GSK) GlaxoSmithKline

 Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

Following a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan ("The Plan"), which is notionally held in GSK Ordinary share ADRs, the Administrators of the Plan notified GlaxoSmithKline plc and the under-mentioned Persons on 6 February 2012 of an increase in the notional allocation of Ordinary share ADRs on 3 February 2012 at a price of $44.85 per ADR:-

This notification relates to a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).

V A Whyte

Company Secretary

6 February 2012

This announcement replaces the original announcement released on 10 January 2012 at 18.22 (RNS No: 3416V).

One of the Non-Executive Director's interests in the Ordinary shares of GlaxoSmithKline plc, indicated with an asterisk (*) below, was incorrectly stated in the announcement made on 10 January 2012.

Save as disclosed above, all other details remain unchanged. The full amended text is shown below.

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the directors' interests in the Ordinary shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc.

On 30 December 2011, the Company's Non-Executive Directors were provisionally allocated the following awards over Ordinary shares and American Depositary Shares (ADSs) in the Company through the annual reinvestment of dividends paid throughout 2011:

GlaxoSmithKline Non-Executive Directors Automatic Share Award and Elected Share Award- Annual Dividend Reinvestment

The Company and the Non-Executive Directors were informed of these allocations on

10 January 2012.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte

Company Secretary

This announcement replaces the original announcement released on 1 July 2011 at 13.42 (RNS No: 6109J).

One of the Non-Executive Director's interests in the Ordinary shares of GlaxoSmithKline plc, indicated with an asterisk (*) below, was incorrectly stated in the announcement made on 1 July 2011.

Save as disclosed above, all other details remain unchanged. The full amended text is shown below.

 Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the directors' interests in the Ordinary shares and American Depository Shares (ADSs) of GlaxoSmithKline plc.

On 30 June 2011, the Company's Non-Executive Directors were provisionally allocated awards over Ordinary shares at a price of £13.20 per Ordinary share and $42.43 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2011 to 30 June 2011:

The Company and the Non-Executive Directors were informed of these allocations on 1 July 2011.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte

Company Secretary